Endonovo Therapeutics Inc (ENDV)

[srinsocal]

These Biotech Companies are a Treat for Investors

HENDERSON, NV / ACCESSWIRE / July 8, 2018 / In order to take a drug to market the cost was estimated to be $2.4 billion. This has caused many biotech firms to enter the device market, rather than drug market.
Medical devices are finding increasing use in the treatment of diseases traditionally targeted with drugs. It is well established that Nervous system disorders are a large and growing challenge. Pills will not save these individuals struggling in pain, which leaves a tremendous opportunity for biomedical engineering to begin solving some of these problems.

These companies are a treat for potential investors: Endonovo Therapeutics, Inc. (ENDV), Geron Corporation (NASDAQ: GERN), Pulse Biosciences, Inc. (PLSE)

Endonovo Therapeutics, Inc. (ENDV)

Market Cap: $13.2M, current share price: $.03

Endonovo Therapeutics is a commercial stage developer of non-invasive medical devices designed to deliver its proprietary Electroceutical Therapy for the treatment of inflammatory conditions, cardiovascular diseases and central nervous system disorders. Endonovo’s Electroceutical Therapy is FDA-Cleared for the palliative treatment of pain and post-surgical edema (swelling) and CE Marked for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. Endonovo’s Electroceutical Therapy has CMS National Coverage for the treatment of chronic wounds. The Company’s current pipeline of clinical-stage Electroceutical Therapies targets cardiovascular diseases and central nervous system disorders, including ischemic heart disease, acute concussions, post-concussion syndrome, traumatic brain injury (TBI) and multiple sclerosis.

http://www.nbcrightnow.com/story/38595426/these-biotech-companies-are-a-treat-for-investors